Thank you for donating!

You can donate using the following services.


  1. 12.09.19

    CTD Holdings to Present at 2019 Annual Conference for NPC Patients, Families, and Health Professionals in the United Kingdom

    CTD is also a proud sponsor of the NPUK Annual Family Conference & Interactive Workshop on Niemann-Pick Diseases, for the 4th year running...

    Read more
  2. 12.09.19

    ASMD Research Study Opportunity

    Evidera, a research group working on behalf of Sanofi Genzyme, is conducting a research study to understand the symptoms and impact experienced by carers of those affected by ASMD Niemann-Pick disease types B, or A/B...

    Read more
  3. 30.08.19


    Copenhagen, Denmark, August 28, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces its interim financial results for the period January 1 – June 30, 2019 and corporate highlights...

    Read more
  4. 26.07.19

    Survey Opportunity: Qualitative Analysis of Niemann-Pick Type C 5-Domain NPCCSS

    We are pleased to inform you of a study opportunity available to NPC patients and their families:
    Clinical Outcomes Solutions (COS), is a research company conducting research into Niemann-Pick type C (NPC) on behalf of a sponsor, Orphazyme A/S, a pharmaceutical company studying NPC...

    Read more
  5. 22.07.19

    Orphazyme to prepare for filing of arimoclomol in US for Niemann-Pick disease Type C (NPC)

    Following the encouraging regulatory agency feedback, Orphazyme plans to introduce an Early Access
    Program for NPC in the fall of 2019, to further accelerate access to treatment with arimoclomol for people
    living with NPC...

    Read more